Lead-Time Corrected Effect on Breast Cancer Survival in Germany by Mode of Detection.

detection mode lead time mammography screening survival

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Mar 2024
Historique:
received: 23 01 2024
revised: 20 03 2024
accepted: 26 03 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 13 4 2024
Statut: epublish

Résumé

(1) Background: Screen-detected breast cancer patients tend to have better survival than patients diagnosed with symptomatic cancer. The main driver of improved survival in screen-detected cancer is detection at earlier stage. An important bias is introduced by lead time, i.e., the time span by which the diagnosis has been advanced by screening. We examine whether there is a remaining survival difference that could be attributable to mode of detection, for example, because of higher quality of care. (2) Methods: Women with a breast cancer (BC) diagnosis in 2000-2022 were included from a population-based cancer registry from Schleswig-Holstein, Germany, which also registers the mode of cancer detection. Mammography screening was available from 2005 onwards. We compared the survival for BC detected by screening with symptomatic BC detection using Kaplan-Meier, unadjusted Cox regressions, and Cox regressions adjusted for age, grading, and UICC stage. Correction for lead time bias was carried out by assuming an exponential distribution of the period during which the tumor is asymptomatic but screen-detectable (sojourn time). We used a common estimate and two recently published estimates of sojourn times. (3) Results: The analysis included 32,169 women. Survival for symptomatic BC was lower than for screen-detected BC (hazard ratio (HR): 0.23, 95% confidence interval (CI): 0.21-0.25). Adjustment for prognostic factors and lead time bias with the commonly used sojourn time resulted in an HR of 0.84 (CI: 0.75-0.94). Using different sojourn times resulted in an HR of 0.73 to 0.90. (4) Conclusions: Survival for symptomatic BC was only one quarter of screen-detected tumors, which is obviously biased. After adjustment for lead-time bias and prognostic variables, including UICC stage, survival was 27% to 10% better for screen-detected BC, which might be attributed to BC screening. Although this result fits quite well with published results for other countries with BC screening, further sources for residual confounding (e.g., self-selection) cannot be ruled out.

Identifiants

pubmed: 38611004
pii: cancers16071326
doi: 10.3390/cancers16071326
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Laura Schumann (L)

Institute of Social Medicine and Epidemiology, University of Luebeck, 23562 Luebeck, Germany.

Moritz Hadwiger (M)

Institute of Social Medicine and Epidemiology, University of Luebeck, 23562 Luebeck, Germany.

Nora Eisemann (N)

Institute of Social Medicine and Epidemiology, University of Luebeck, 23562 Luebeck, Germany.

Alexander Katalinic (A)

Institute of Social Medicine and Epidemiology, University of Luebeck, 23562 Luebeck, Germany.
Institute of Cancer Epidemiology, University of Luebeck, 23562 Luebeck, Germany.

Classifications MeSH